All News

I may be ready to sign up for a big race to celebrate three years cancer-free, but it turns out that the fear of recurrence may never be far from my mind.

Debra Pratt, from the Cleveland Clinic Breast Health Center, writes that early detection and lifestyle changes can help save lives.

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

While nearly 70 percent of patients and survivors agreed that working helps in their treatment and recovery, they acknowledged that cancer is accompanied by particular challenges in the workplace.

With pink popping up all over, and public service announcements everywhere we turn, it would be impossible to forget that October is Breast Cancer Awareness Month. When this month coincides with a personal experience with cancer, the messages become even more powerful. Mammograms do save lives. Tell a friend, tell a parent, tell a child.

Before I was diagnosed with metastatic melanoma, I lived in the sweet spot — both in life and in running.

Immunotherapy – it's the buzzword of the moment. It would be difficult to imagine an area of the field generating more excitement and hope than immuno-oncology is sparking right now.

If there is one thing that all cancers have in common, it's fear. Whether it is the fear of a known, of the unknown, of loss, or fear of pain and suffering, fear is one of the primary symptoms of this diagnosis.

Breast cancer and melanoma survivor ponders the impact of cancer on her capacity to cope with life changes.

The agent gained a priority review designation for use in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy, based on findings from the phase 3 ENDEAVOR trial.

Question: When do cancer scans shift from disease monitoring to routine checkups? Answer: You decide.

Two transplants, three mini triathons. Running the race for myself and others shows how lessons learned in the hospital translate to victory on the outside.

Each phone call started the same way and ended with more bad news.

Since May, Stonestreet, who plays the character of "Cameron" on the popular sitcom, has been helping Bristol-Myers Squibb publicize its contest for charitable donations — called Ready. Raise. Rise.

Questions persist regarding mechanisms of PD-L1 overexpression in lymphoid malignancies, patient selection, biomarkers to guide therapy and predict response, and identification of agents to use in combination with PD-1/PD-L1 inhibitors.

Jame Abraham, Director of Cleveland Clinic's Breast Medical Oncology Program, provides an overview of what you shouldn't be afraid to ask your doctor.

Thoughts on losing my last shred of dignity during breast cancer treatment and the Mardi Gras beads I earned along the way.

When nothing else seemed to be working, I searched for some "alternative" alternatives.

Every year around October, the Susan G. Komen Foundation hosts a "Race for the Cure."

The approval is based on data from the phase 3 CheckMate-057 trial, in which second-line Opdivo reduced the risk of death by 28 percent versus docetaxel in patients with nonsquamous NSCLC.

Genetic testing is becoming more prevalent and as an advocate for those with hereditary cancer syndromes, I spend countless hours talking to people who have had genetic testing without seeing a certified genetic counselor.

Traditional treatment options for breast cancer include surgery, chemotherapy, radiation and anti-hormone therapies but there are other options available.

Male breast cancer survivor Khevin Barnes looks back on the longest year of his life.

Cancer is more than cancer awareness and it isn't just about the "popular" cancers.

The approval was based on findings from the phase 3 EF-14 trial.

A novel service model allowed for shorter durations of treatment with radiation, fewer unfinished treatments with radiation, shorter hospital stays and increased use of palliative care.

I've often heard from people who've gone through traumatic experiences that their perspectives shifted and revealed previously unknown qualities.

The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.